Last reviewed · How we verify
TPX-100 200mg, Once weekly for 4 weeks
TPX-100 200mg, Once weekly for 4 weeks is a Small molecule drug developed by OrthoTrophix, Inc. It is currently in Phase 2 development.
At a glance
| Generic name | TPX-100 200mg, Once weekly for 4 weeks |
|---|---|
| Sponsor | OrthoTrophix, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPX-100 200mg, Once weekly for 4 weeks CI brief — competitive landscape report
- TPX-100 200mg, Once weekly for 4 weeks updates RSS · CI watch RSS
- OrthoTrophix, Inc portfolio CI
Frequently asked questions about TPX-100 200mg, Once weekly for 4 weeks
What is TPX-100 200mg, Once weekly for 4 weeks?
TPX-100 200mg, Once weekly for 4 weeks is a Small molecule drug developed by OrthoTrophix, Inc.
Who makes TPX-100 200mg, Once weekly for 4 weeks?
TPX-100 200mg, Once weekly for 4 weeks is developed by OrthoTrophix, Inc (see full OrthoTrophix, Inc pipeline at /company/orthotrophix-inc).
What development phase is TPX-100 200mg, Once weekly for 4 weeks in?
TPX-100 200mg, Once weekly for 4 weeks is in Phase 2.